SUMMARY Polymorphonuclear leucocyte (PMN) functions (migration in vitro, chemiluminescence, 02 production, binding of chemotactic peptide, and aggregation) were studied in HLA-B27 positive patients with previous yersinia arthritis (YA). PMNs of patients whose disease had been severe showed chemokinetic and chemiluminescence responses significantly higher than the PMNs of those with a mild disease. The results support the view that enhanced PMN function contributes to inflammatory symptoms in patients with YA.
Both reactive arthritis, such as enteroarthritis following an infection caused by Yersinia enterocolitica, and ankylosing spondylitis are associated with the histocompatibility antigen HLA-B27. ' The mechanism of this association and the pathogenesis of the HLA-B27 linked diseases remain unknown, but exaggerated inflammatory responsiveness may be involved.2 3This is supported by the findings that polymorphonuclear leucocytes (PMNs) of HLA-B27 positive subjects, with or without yersinia arthritis (YA), and also those of patients with ankylosing spondylitis show higher chemotaxis in vitro than do PMNs of HLA-B27 negative healthy subjects. 4 In addition, zymosan activated sera from HLA-B27 positive subjects stimulate PMN motility in vitro more than do such sera from HLA-B27 negative subjects. 6 The relevance of these findings to the in vivo conditions has been confirmed by means of a skin chamber technique. 7 To see whether a correlation can be found between enhanced PMN responsiveness and the severity of YA we compared PMN functions in two 
Patients and methods

PATIENTS
Twenty four HLA-B27 positive patients with previous YA from a follow up study were assigned to two groups on the basis of their clinical characteristics during the acute phase of the disease (Table 1) . The mean intervals between the acute phase of YA and the time of the present study were 8-5 years (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in group I and 8-6 years (5-11) in group II. Two patients, one in each group, were studied simultaneously, and the pairs were matched for age and sex (three pairs were matched only for age). At the time of the present study one patient in each group was taking indomethacin (75-100 mg/day), the others were free of symptoms and signs of active disease.
CELLS
Buffy coat cells for the migration assays were separated from heparinised venous blood by dextran sedimentation. PMNs (95-99% pure) for other The method of Pick and Mizel14 was used as described'5 to determine 02 production of PMNs. fMLP (10-6, 10-7, and 10-8 M) was used as the stimulus. Incubation periods were 15, 30, and 60 min. The coefficient of variation was 7-25%.
f-Met-Leu-(QH)Phe BINDING ASSAY Binding was assayed largely as described by Wil- liams et al. 16 Fifty microlitres of f-Met-Leu-(3H)Phe (New England Nuclear, Boston, Massachusetts; specific activity 48-3 Ci/mmol (1- PMNs/ml) of each patient. An aliquot of 0-3 ml of the PMN suspension (10O0x106/ml) was added to a siliconised cuvette containing a siliconised stirring (11) 62 (9) 61 (13) 51 (8) 61 (12) 54 (13) 50 (12) 58 (10) 64 (18) 50- tAbbreviations: HSA=human serum albumin; ZAS=zymosan activated serum; fMLP=N-formyl-methionyl-leucyl-phenylalanine.
tThe significance of the difference between the two groups (paired sample t test) is indicated as follows: *p<0-05, **p<0-01. §Detailed data are presented in Fig. 1 . In the agarose assay the group I PMNs showed higher chemokinetic migration in fMLP at the optimal 10-8 M concentration (Table 2, Fig. 1B) . Chemotactic migration towards fMLP was higher in nine out of 12 pairs, but the difference was not statistically significant. No major differences were found in spontaneous locomotion, or chemokinetic or chemotactic locomotion induced by ZAS ( Table 2) .
We also tested the patients' sera for their ability to stimulate chemokinetic locomotion of the cells of one healthy blood donor by means of the membrane filter assay. No significant differences were found between the two groups tested in parallel using fresh sera, heated (56°C, 30 min) sera, ZAS, and heated ZAS (data not shown).
CHEMILUMINESCENCE
The shape of the curves was the same in both groups, with a single peak 1-2 min or 5-7 min after adding fMLP or zymosan respectively (Fig. 2) . That only one peak was found with fMLP was probably because the cells had been kept at room temperature for two to three hours before testing.'8 The group I PMNs tended to display higher responses to both zymosan and fMLP (Fig. 2) . In studies with zymosan the mean areas (SD) under the curves and the mean heights (SD) of the maximal responses in groups I and II were 52-5 (18-0) and 44.1 cm2 (Fig. 3A) and 131 (52) and 105 (38) mV respectively. The differences between the two groups were not statistically significant. In studies with fMLP the areas under the curves were significantly larger in group I than in group II (p<0-02, heights of the maximal responses to fMLP were 44 (20) and 31 (18) mV in groups I and II respectively (not statistically significant).
PRODUCTION OF 02
The maximum response was achieved with 10-6 M fMLP during a one hour incubation. There were no statistically significant differences between groups I and II in the maximal responses (mean (SD): 41 108 (35) fmol/106 PMNs) than group II PMNs (89 (27)), but the difference was not statistically significant (Fig. 4) .
AGGREGATION
The tracings of the aggregation responses to 10-5 M fMLP were of uniform shape in both groups. They reached a peak in one to two minutes and showed slow disaggregation thereafter. Neither the maximal responses (Fig. 5) nor the areas under the curves showed statistically significant differences between the two groups, the mean (SD) responses in groups I and II being 24*2 (3-9) and 25-7 (5.7) cm, and 28-2 (5.0) and 28-6 (6.4) cm2 respectively. with previous YA. The results indicate that both migratory and oxygen radical producing capacities of PMNs from patients who had had severe YA (high erythrocyte sedimentation rate, high white blood cell count, high prevalence of extra-articular manifestations) were higher than in patients whose disease had been mild.
To migrate under agarose PMNs may have to deform less than in the filter,19 and their distances of migration are 50-to 100-fold greater. We therefore used the two assays in parallel. Group I PMNs showed enhanced chemokinesis both under agarose and in filter, though towards different attractants.
The reason for the discrepancy is not known, but it may involve differences in the character of the two methods.
In the chemiluminescence assay the group I PMNs tended to display higher responses to both zymosan and fMLP, whereas spectrophotometric assessment of O2 production showed no differences between the groups. The latter technique, however, detects only reduction of cytochrome c sensitive to superoxide dismutase, whereas in the chemiluminescence assay combined actions of O2, hydrogen peroxide, and myeloperoxidase on the oxidation of luminol can be measured.2(
The capacity of the cells to bind radiolabelled fMLP can be taken as an estimate of the amount of fMLP receptors on the PMNs. The group I neutrophils bound slightly more fMLP than the group II cells.
We found no difference between the two groups in the aggregation assay, which measures the adherence of PMNs to each other. PMN aggregation and adhesion to surfaces, however, may be separate cell functions,2' 22 and it might be interesting to compare the groups using an assay measuring the adherence of PMNs to surfaces, such as endothelial cell monolayers.
In conclusion, the results show that among HLA-B27 positive patients the severity of the acute YA correlates with enhanced PMN function. The interval between the acute phase of the disease and the present study was five to 14 years, and thus the cells seem to retain their high responsiveness even in the absence of clinically active disease. At 
